After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

With AI advancements upending the role of senior executives, the question is what the C-suite transformation should look like ...

These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. In other recent news, Recursion Pharmaceuticals reported its second-quarter 2025 earnings, highlighting ...